Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema

Humanistic burden and health-related quality of life

8 evidence topics · 7 sources

Multinational adult survey: treatment exposure and quality-of-life outcomes
MeasureReported result
Participants included“260”
Participants using any long-term prophylaxis“153 (58.8%)”
First-line prophylaxis among prophylaxis users, per study classification“56/153 (36.6%)”
AE-QoL total score, mean ± SD“42.9 ± 23.2”
Participants with AE-QoL total score ≥39“137 of 260 (52.7%)”
Moderate to severe anxiety by HADS“69 (26.5%)”
Moderate to severe depression by HADS“27 (10.4%)”